Literature DB >> 23952613

Characterization of interactions between heparin/glycosaminoglycan and adeno-associated virus.

Fuming Zhang1, Javier Aguilera, Julie M Beaudet, Qing Xie, Thomas F Lerch, Omar Davulcu, Wilfredo Colón, Michael S Chapman, Robert J Linhardt.   

Abstract

Adeno-associated virus (AAV) is a key candidate in the development of gene therapy. In this work, we used surface plasmon resonance spectroscopy to study the interaction between AAV and heparin and other glycosaminoglycans (GAGs). Surface plasmon resonance results revealed that heparin binds to AAV with an extremely high affinity. Solution competition studies showed that binding of AAV to heparin is chain length-dependent. AAV prefers to bind full chain heparin. All sulfo groups (especially N-sulfo and 6-O-sulfo groups) on heparin are important for the AAV-heparin interaction. Higher levels of sulfo group substitution in GAGs enhance their binding affinities. Atomic force microscopy was also performed to image AAV-2 in a complex with heparin.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23952613      PMCID: PMC3859860          DOI: 10.1021/bi4008676

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  55 in total

1.  The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy.

Authors:  Qing Xie; Weishu Bu; Smita Bhatia; Joan Hare; Thayumanasamy Somasundaram; Arezki Azzi; Michael S Chapman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-22       Impact factor: 11.205

2.  Analysis of site-specific transgene integration following cotransduction with recombinant adeno-associated virus and a rep encodingplasmid.

Authors:  Nadja A Huttner; Anne Girod; Susanne Schnittger; Claudia Schoch; Michael Hallek; Hildegard Büning
Journal:  J Gene Med       Date:  2003-02       Impact factor: 4.565

3.  Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity.

Authors:  N Kaludov; K E Brown; R W Walters; J Zabner; J A Chiorini
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors.

Authors:  Atsushi Handa; Shin-Ichi Muramatsu; Jianming Qiu; Hiroaki Mizukami; Kevin E Brown
Journal:  J Gen Virol       Date:  2000-08       Impact factor: 3.891

5.  Adeno-associated virus (AAV) site-specific integration: formation of AAV-AAVS1 junctions in an in vitro system.

Authors:  J Dyall; P Szabo; K I Berns
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

6.  Insect cells as a factory to produce adeno-associated virus type 2 vectors.

Authors:  Masashi Urabe; Chuantian Ding; Robert M Kotin
Journal:  Hum Gene Ther       Date:  2002-11-01       Impact factor: 5.695

7.  Enzymatic modification of heparan sulfate on a biochip promotes its interaction with antithrombin III.

Authors:  M Hernaiz; J Liu; R D Rosenberg; R J Linhardt
Journal:  Biochem Biophys Res Commun       Date:  2000-09-16       Impact factor: 3.575

8.  Structural studies of the interaction of Crataeva tapia bark protein with heparin and other glycosaminoglycans.

Authors:  Fuming Zhang; Benjamin Walcott; Dongwen Zhou; Alla Gustchina; Yi Lasanajak; David F Smith; Rodrigo S Ferreira; Maria Tereza S Correia; Patrícia M G Paiva; Nicolai V Bovin; Alexander Wlodawer; Maria L V Oliva; Robert J Linhardt
Journal:  Biochemistry       Date:  2013-03-14       Impact factor: 3.162

Review 9.  Heparin-protein interactions.

Authors:  Ishan Capila; Robert J Linhardt
Journal:  Angew Chem Int Ed Engl       Date:  2002-02-01       Impact factor: 15.336

10.  Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding.

Authors:  Shaun R Opie; Kenneth H Warrington; Mavis Agbandje-McKenna; Sergei Zolotukhin; Nicholas Muzyczka
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

View more
  19 in total

1.  AAVR: A Multi-Serotype Receptor for AAV.

Authors:  Candace Summerford; Jarrod S Johnson; R Jude Samulski
Journal:  Mol Ther       Date:  2016-04       Impact factor: 11.454

2.  Glycan Determinants of Heparin-Tau Interaction.

Authors:  Jing Zhao; Isabelle Huvent; Guy Lippens; David Eliezer; Anqiang Zhang; Quanhong Li; Peter Tessier; Robert J Linhardt; Fuming Zhang; Chunyu Wang
Journal:  Biophys J       Date:  2017-03-14       Impact factor: 4.033

3.  Glycomic and Proteomic Changes in Aging Brain Nigrostriatal Pathway.

Authors:  Rekha Raghunathan; Nicole K Polinski; Joshua A Klein; John D Hogan; Chun Shao; Kshitij Khatri; Deborah Leon; Mark E McComb; Fredric P Manfredsson; Caryl E Sortwell; Joseph Zaia
Journal:  Mol Cell Proteomics       Date:  2018-06-18       Impact factor: 5.911

4.  Novel method for measurement of heparin anticoagulant activity using SPR.

Authors:  Jing Zhao; Xinyue Liu; Anju Malhotra; Quanhong Li; Fuming Zhang; Robert J Linhardt
Journal:  Anal Biochem       Date:  2017-03-18       Impact factor: 3.365

5.  Hepatocyte Heparan Sulfate Is Required for Adeno-Associated Virus 2 but Dispensable for Adenovirus 5 Liver Transduction In Vivo.

Authors:  Anne K Zaiss; Erin M Foley; Roger Lawrence; Lina S Schneider; Hamidreza Hoveida; Patrick Secrest; Arthur B Catapang; Yu Yamaguchi; Ramon Alemany; Dmitry M Shayakhmetov; Jeffrey D Esko; Harvey R Herschman
Journal:  J Virol       Date:  2015-10-21       Impact factor: 5.103

Review 6.  Perspective on Adeno-Associated Virus Capsid Modification for Duchenne Muscular Dystrophy Gene Therapy.

Authors:  Michael E Nance; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2015-10-15       Impact factor: 5.695

7.  Electron microscopy analysis of a disaccharide analog complex reveals receptor interactions of adeno-associated virus.

Authors:  Qing Xie; Michael Spilman; Nancy L Meyer; Thomas F Lerch; Scott M Stagg; Michael S Chapman
Journal:  J Struct Biol       Date:  2013-09-11       Impact factor: 2.867

8.  An Alternate Route for Adeno-associated Virus (AAV) Entry Independent of AAV Receptor.

Authors:  Amanda M Dudek; Sirika Pillay; Andreas S Puschnik; Claude M Nagamine; Fang Cheng; Jianming Qiu; Jan E Carette; Luk H Vandenberghe
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

9.  Differential adeno-associated virus serotype-specific interaction patterns with synthetic heparins and other glycans.

Authors:  Mario Mietzsch; Felix Broecker; Anika Reinhardt; Peter H Seeberger; Regine Heilbronn
Journal:  J Virol       Date:  2013-12-26       Impact factor: 5.103

10.  A Haploid Genetic Screen Identifies Heparan Sulfate Proteoglycans Supporting Rift Valley Fever Virus Infection.

Authors:  Amber M Riblett; Vincent A Blomen; Lucas T Jae; Louis A Altamura; Robert W Doms; Thijn R Brummelkamp; Jason A Wojcechowskyj
Journal:  J Virol       Date:  2015-11-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.